Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: BioMérieux, MyHealthChecked, Biocare Medical, Molecular Instruments, More

NEW YORK – BioMérieux said this week that it has acquired Lumed, a developer of clinical decision support software. BioMérieux increased its stake in the Quebec, Canada-based firm from 16 percent to 100 percent, representing an investment of approximately 9 million ($9.9 million). Lumen's software is intended to help antimicrobial stewardship teams improve daily workflow and to optimize care delivery, cost, and patient management. The two firms have collaborated since 2017. 

MyHealthChecked this week reported £11 million ($14 million) in preliminary 2023 revenues, down from £22.3 million in 2022. COVID lateral flow tests still account for the majority of revenues for the Cardiff, UK-based consumer home testing healthcare company. "Whilst revenue has, as expected, reduced compared to the prior year, the seasonality of respiratory infections drove an uplift in demand during the second half, and we expect that COVID testing will remain an ongoing annual requirement for customers," CEO Penny McCormick said in a statement. At the end of 2023, MyHealthChecked had £7.8 million in cash left. 

Biocare Medical and Molecular Instruments (MI) have partnered to combine Biocare Medical's expertise in automated bioimaging systems with MI's suite of HCR products to enable automated in situ hybridization and immunohistochemistry. MI's HCR imaging technology features mild sample preparation with no protease digestion, isothermal amplification at room temperature, and both fluorescent and brightfield imaging, while its HCR RNA-ISH assay is optimized to preserve tissue morphology and integrates seamlessly with existing IHC/IF workflows, the company said. Integrating the HCR Platform into Biocare Medical's ONCORE Pro X instrument will enable faster turnaround times and throughput, the company added. 

Israeli targeted DNA sequencing company Sequentify said this week that it has received an undisclosed amount of funding from the Israel Innovation Authority. The grant, which is part of a $1.3 million project, will support the development of the company's targeted sequencing panel for infectious disease research. The goal is to generate a culture-free test that focuses on pathogen diagnosis and antibiotic resistance surveillance. Rehovot-based Sequentify said the project is part of its efforts to enhance the utility of its ultra-fast InfiniSeq technology in the area of infectious diseases.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.